Persistent Pulmonary Artery Hypertension After Valve Replacement

Persistence of Severe Pulmonary Artery Hypertension in Patients After vaLve replacemenT

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01238731

Acronym

SALT

Enrollment

300

Registered

2010-11-11

Start date

2011-01-31

Completion date

2012-03-31

Last updated

2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Severe PH After Valve Therapy

Keywords

Valve replacement, pulmonary hypertension, long term follow up

Brief summary

Background: Persistent severe pulmonary hypertension (PH) after mechanical valve replacement is a frequent finding in patients with severe valve-diseases. The reasons to develop PH are multifactorial and the prevalence of severe PH significantly worsens the patients´ outcome. Aims: (i) To define the prevalence of PH in patients after valve replacement and (ii) to identify factors predicting persistent PH. Methods: All patients which underwent valve replacement at our institution between the years 2008 -2010 will be screened retrospectively. Those patients with pre- procedural proven PH by means of right-heart catheterization will receive prospective follow-up with echocardiography. Diagnosis of persistent PH will be confirmed with right heart catheterization.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Proven pulmonary hypertension before valve replacement and informed consent for data acquisition

Exclusion criteria

* patients do not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Persistence of pulmonary hypertension after valve replacement for treatment of severe valve disease	> 6 months after valve therapy

Secondary

Measure	Time frame
MACCE, all cause mortality during FU	Within 24 months after valve therapy

Countries

Germany

Contacts

Primary ContactChristoph Hammerstingl, MD

christoph.hammerstingl@ukb.uni-bonn.de+4922815951

Backup ContactDirk Skowasch, MD, PhD

dirk.skowasch@ukb.uni-bonn.de+4922816076

Outcome results